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ABSTRACT: The objective of this research is to outline the liberation of indomethacin from different chitosan gels containing O/W
microemulsion. The influence of surfactant, sodium lauryl sulfate, in two concentrations (0.5% and 0.75%, w/w) was determined in
dissolution medium on the release of indomethacin, which was used as poor water-soluble model drug. Chitosan gels were prepared in
four different concentrations of chitosan—1%, 1.5%, 2%, and 3% (w/w). Microemulsion enhanced the liberation of the indomethacin
from chitosan gels into all dissolution mediums. Adding the surfactant into phosphate-buffered saline decreased the amount of liberated
indomethacin from microemulsion, gel mixture, but increased the drug liberation from pure chitosan gels. It was detected that with the
increased concentration of chitosan in the samples, the amount of indomethacin liberated (p < 0.05) also increased. A conclusion was
drawn that the liberation of indomethacin from chitosan gels was influenced by increased pH of the samples. The high viscosity induced
a higher release of indomethacin from 3% (w/w) chitosan hydrogel at pH 5.8 as compared with 3% (w/w) chitosan hydrogel at pH 3.8.
The highest percentage of released indomethacin was determined when a mixture of microemulsion gel with higher chitosan content was
used. C© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3977–3984, 2014
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INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely
used as analgesics and for the treatment of local and systemic
inflammatory pathologies. The limited efficacy of these agents,
coupled with the strong predisposition to cause gastrointesti-
nal (GIT)-associated adverse effects and nephrotoxicity via con-
ventional routes prompted for exploitation of alternative drug
delivery systems, for example, transdermal delivery.1 The main
drive behind topical application of NSAIDs is that blood con-
centrations are typically less than 1/20th of those found in per-
orally used NSAIDs, minimizing the risk of serious harm.2 Op-
timization of the systemic profile of indomethacin by controlled
input of the drug via transdermal delivery has been shown to
reduce GIT and central nervous system-related side effects.3
Approximately 40% of new chemical entities exhibit poor
aqueous solubility and present major challenge to modern drug
delivery systems because of poor absorption, poor bioavailabil-
ity, and lack of dose proportionality.4 The selected drug for the
study was indomethacin, which is an anti-inflammatory agent
having low solubility. The preferred route of topical administra-
tion for indomethacin is either dermally or transdermally, for
that reason it has to penetrate into the deeper skin layers or per-
meate the skin. Most topically administered drugs do not have
the ability to penetrate the stratum corneum. In these cases,
modulations of the skin penetration profiles of these drugs and
skin barrier manipulations are necessary. A skin penetration
enhancement can be achieved chemically, physically, or by use
of appropriate formulations.5
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By the in vitro assessment of dissolution properties of some
low-solubility compounds, adequate dissolution cannot be ob-
tained with aqueous solutions within physiologic pH ranges. It
is optional for these solutions to utilize surfactant to enhance
drug solubility. Commonly acceptable are ionic or nonionic sur-
factants, including sodium lauryl sulfate (SLS). A surfactant
can be used as either a wetting agent or, when the critical
micelle concentration (CMC) is reached, to solubilize the drug
substance. The amount of surfactant needed for adequate drug
solubility depends on the surfactant’s CMC and the degree to
which the compound partitions into the surfactant micelles. On
the contrary, surfactant’s CMC depends on the surfactant itself
and the ionic strength of the dissolution medium.6
Sodium lauryl sulfate was used as a model anionic surface-
active compound because its properties in aqueous solutions
are well characterized.7 Various studies have reported the in-
fluence of surfactants on dissolution of pharmaceutical active
ingredients.8–11 Surfactants are employed in dissolution stud-
ies because natural surfactants in the body aid in the dissolu-
tion and subsequent absorption of drugs with limited aqueous
solubility.12 Topical preparations are mostly used for the local
effects on the site of their application by virtue of drug penetra-
tion into the underlying layers of skin or mucous membranes.13
The barrier for topical delivery is skin, which makes the
drug delivery difficult. Taking this factor into consideration,
microemulsions as the colloidal vehicle systems offer very good
conditions for the fast and deep penetration of biologically ac-
tive substances into the skin layer.14,15 Moreover, it has been
reported that the ingredients of microemulsions may reduce
the diffusion barrier of the stratum corneum and enhance the
permeation of drug. Hence, it is promising for both transder-
mal and dermal delivery of drugs as an efficient route of drug
administration. However, the low viscosity of microemulsion re-
strains its application in the pharmaceutical industry.16,17 The
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main advantage of microemulsions over the current formula-
tions like topical gels and solutions used for treating pain or
inflammation is high-solubilizing capacity for lipophilic drugs
and enhanced topical drug availability.18,19 They can also influ-
ence a drug release from the formulation to enhance absorption
or to lower toxicity.20
Even though microemulsions offer several advantages for
delivery, it is difficult to adjust the system for convenient top-
ical application because of low viscosity. This problem can be
overcome by using polymers such as chitosan as gelling agent.
Chitosans are linear cationic polysaccharides that are
prepared by (partial) N-deacetylation of chitin, an abun-
dant structural polysaccharide contained in crab and shrimp
shells. Chitosans consist of (1→4)-linked 2-acetamido-2-deoxy-
b-D-glucopyranose (GlcNAc) and 2-amino-b-D-glucopyranose
units.21 Chitosan is regarded as such valuable natural biocom-
patible polymer because it is nontoxic, biodegradable, mucoad-
hesive, easily bioabsorbable, and also possesses gel-forming
ability at low pH.22 Both the number of GlcNAc units (degree
of acetylation) and the molecular weight of chitosans have been
shown to influence the physical and biological properties of the
polymer.21 At relatively low pH (<6.5), chitosan is positively
charged and tends to be soluble in dilute aqueous solutions,
but at higher pH it tends to lose its charge and may precipitate
from solution because of deprotonation of the amino groups.7
Because of its polymeric cationic characteristics, chitosan can
interact with negatively charged molecules or polymers.23 Chi-
tosan acts as a penetration enhancer by opening the tight ep-
ithelial junctions and hence is particularly exploited in protein
and vaccine delivery.24 Another important application of chi-
tosans in industry is the development of drug delivery systems.
The use of controlled-release systems has certain advantages
as compared with conventional dosage forms, as they can min-
imize side effects, and prolong the efficacy of the drug. These
dosage forms regulate the drug release rate and can reduce the
frequency of administration of the drug, thus assuring better
patient compliance. Pulsatile delivery systems based on chi-
tosan have also been described, which are interesting with re-
gard to adjusting drug release to physiological needs of the
body, as in the case of hormone release. The potential of chi-
tosan as a novel excipient, which might yet receive extensive
application in pharmaceutical products, has been highlighted
in several reports.25
In our previous studies, we have investigated in vivo local
anesthetic effects and acute toxicity of carbamate local anes-
thetics as carbisocaine, heptacaine, and pentacaine applied in
W/O microemulsion vehicles.26–28 Later, we studied bicontinu-
ous gel-like microemulsion dispersed systems as a vehicle for
NSAIDs—indomethacin and diclofenac. Their permeation pro-
files through excised hairless rat skin in the in vitro experiment
were determined.13 The effect of microemulsion on liberation
of indomethacin from hydrophilic (carbopol) and lipophilic gel
(aerosil in liquid paraffin) was also evaluated.29
In this study, chitosan hydrogel formulations containing mi-
croemulsion as vehicles for indomethacin as drug were studied.
MATERIALS AND METHODS
Materials
Indomethacin [1-(p-chlorobenzoyl)-5-methoxy-2-methyl-
1H-indole-3-acetic acid] was obtained from Merck KGaA
(Darmstadt, Germany). Chitosan (medium molecular weight,
MMW, Brookfield viscosity 200,000 cps), oil phase, and surfac-
tant were obtained from Sigma-Aldrich Chemie GmbH (Stein-
heim, Germany), analytical-grade SLS was purchased from
SigmaChemical Company (St. Louis,Missouri). All other chem-
icals used were of analytical reagent grade. Purified water was
used for the preparation of all samples.
Methods
Preparation of the Microemulsion Systems
The microemulsion composed of 24% (w/w) rosemary oil, 30%
(w/w) water, and 46% (w/w) Tween80/IPA as surfactant–
cosurfactant mixture (S/CoS) in ratio of 3:1 was prepared. The
composition of the microemulsion was chosen according to pre-
liminary trials. Rosemary oil and S/CoS mixture were mixed
in the chosen concentrations, and then water was added drop-
wise with continuous stirring. The system was stored at room
temperature in a tightly closed glass container until further
use.
Preparation of Gels
Chitosan gels were prepared at 1%–3% (w/w) concentration in
dilute lactic acid solution 1% (w/w). Indomethacin was incorpo-
rated into the formulations at 1% (w/w) concentration. The pH
of each formulation was determined after 24 h hydration (pH
meter, HI 991001; Hanna Instruments Ltd., SK). The mixture
was stirred manually for 10 min and sonicated for 30 min.
Preparation of Microemulsion Chitosan Gel Samples
The appropriate amounts of indomethacin, microemulsion, and
chitosan gel were weighed in the ratio 0.5:1:4. Indomethacin
was added in a concentration of 1% (w/w). The mixture was
mixed by using a magnetic stirrer (0.8 cm), until the samples
were homogenized.
Dissolution Media
Preparation of phosphate buffer saline (PBS) pH 7.4 was pre-
pared by mixing appropriate volumes of 1.6 mM KH2PO4,
5.1 mM Na2HPO4, and 154 mM NaCl. SLS was dissolved with
the PBS (pH 7.4) in the concentration of 0.5% and 0.75% (w/w).
Rheological Characterization
Rheological experiments were performed to examine the vis-
cous and elastic properties of the different formulations. Vis-
cosity measurements of gels were performed on a controlled
rate rotational viscometer (Viscotester VT 500, HAAKE, Berlin,
Germany) at 20◦C temperature.
Texture Analysis
A Texture Analyser TA.XT Plus (Stable Micro Systems Ltd.,
Surrey, UK) was used to determine the texture properties of
the chitosan hydrogels. The gel formulation (60 g) was filled in
a standard beaker (100 mL) and was kept in the ultrasonic wa-
ter bath to remove air bubbles for 45 min. The disc was moved
1mm from the bottom of the gel and rested for 30 s to relieve air
bubbles under the disc. Starting point for the 35-mm disc was
submerged (10mm) and rested for 30 s. A disc (35mmdiameter)
was pushed at a speed of 4mm/s for a distance of 10mm into the
hydrogel and redrawn. Five replicate analyses were run with
30 s rest between every run at room temperature for each for-
mulation. Data collection and calculation were performed using
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Table 1. pH Values of Chitosan Hydrogels (Without Microemulsion) and Surface Tension Values of Dissolution Mediums with SLS at the End
of 6 h of Release Through NephrophanR© (n = 5)
Type of Hydrogel and
Concentration (%,
w/w)
pH Values of
Chitosan
Hydrogels
Initial Surface
Tension of PBS with
0.5% SLS ((, mN/m)
Final Surface
Tension of PBS with
0.5% SLS ((, mN/m)
Initial Surface
Tension of PBS with
0.75% SLS ((, mN/m)
Final Surface
Tension of PBS with
0.75% SLS ((, mN/m)
– – 35.874 ± 0.099 – 35.312 ± 0.091 –
Chitosan, 1 3.30 35.914 ± 0.066 35,415 ± 0.058
Chitosan, 1.5 3.80 36.154 ± 0.106 35,865 ± 0.089
Chitosan, 2 4.02 36.553 ± 0.210 36,413 ± 0.143
Chitosan, 3 5.80 36.784 ± 0.247 36,442 ± 0.185
the Texture Exponent 32 (3.0.5.0) software package of the in-
strument. Gel parameters such as hardness, cohesiveness, and
adhesiveness were determined from the resultant force–time
plot. The maximum force does hereby present the hardness of
the hydrogel formulation. Cohesiveness is defined as the work
required to deform the hydrogel in the down movement of the
probe. The second area shows the adhesiveness of the hydrogel
to the probe.30
Surface Tension Measurement
The surface tension of the selectedmediumswas determined by
drop count method, using Traube’s stalagmometer. The stalag-
mometer was filled with purified water above the upper mark.
Using the screw pinch cork, the flow rate was adjusted to 10–
15 drops/min. The number of drops of water was counted be-
tween themarks of the stalagmometer (n1). Water was removed
and the stalagmometer was filled with PBS (pH 7.4) contain-
ing SLS in concentration 0.5% or 0.75% (w/w) and number of
drops was counted (n2). All dissolution mediums with SLS were
measured again after 6 h of liberation of a sample. The surface
tensions of the dissolution mediums were determined using
formula given below.
Surfacetension((2) = n1D2(1/n2D1
where n1 is number of water drops, n2 is number of drops of
sample, D1 is density of water (0.99820 g/mL; 20◦C), D2 is density
of sample, and (1 is surface tension of water (72.8 mN/m)
In Vitro Release of Drug
The release of indomethacin from different chitosan gels and
their mixtures with microemulsion was determined by us-
ing Franz diffusion cells with dialysis cellulose membrane
(NephrophanR©; VEB Filmfabrik, Wolfen, Germany). The artifi-
cial membrane was mounted between the receptor and donor
compartments. The donor compartment was charged with 1.2 g
of samples. The receptor compartment was filled with volume of
PBS (pH 7.4) containing SLS in concentration 0.5% and 0.75%
(w/w), which was maintained at 37 ± 0.5◦C and stirred by mag-
netic bar at 200 ± 5 rpm. The available diffusion area of cell
was 2.54 cm2. The system was maintained throughout the ex-
periment at 37◦C. Five milliliter of medium was withdrawn at
intervals of 15, 30, 45, 60, 90, 120, 180, and 360 min. The vol-
ume of each sample was replaced by the same volume of fresh
buffer to maintain constant volume. Samples were analyzed
for content of indomethacin spectrophotometrically at 8max =
320 nm (UV/VIS spectrophotometer, Phillips PV 9652 UV/VIS,
Phillips, Cambridge, Great Britain).
Statistical Analysis
Experimental results were expressed as mean ± SD (n = 6).
Student’s t-test was applied to control significant differences
in drug release from different formulations. Differences were
considered to be statistically significant at p < 0.05.
RESULTS AND DISCUSSION
Gels were prepared from chitosan (Table 1), after overlaying
of lactic acid in different concentrations and readymade O/W
microemulsion was used. Microemulsion shows the Z-average
diameter of 21.60 nm and the polydispersity index 0.125 (Ze-
tasizer Nano NS ZEN3600; Malvern Instruments Ltd, Worces-
tershire, UK).
The effect of microemulsion on the chitosan gels was eval-
uated by change of color, clarity, and viscosity. After addition
of the microemulsion into the chitosan hydrogels, the mixture
stayed opalescent and viscous.
Rheological measurements of chitosan gels show that they
exhibit pseudoplastic flow in the 1%, 1.5%, and 2% concentra-
tion (Fig. 1). Gels (3%) of chitosan have slightly thixotropic
behavior, which is more apparent in higher pH value (Figs. 2
and 3).
Texture profile analysis was used to investigate effects of
pH of the formulation on the mechanical properties of 3% chi-
tosan gels. The amount of lactic acid is expected to affect the
pH of the formed hydrogel. The texture analysis can determine
the changes of gel properties in relation to the changes in pH
of the gel formulation. The chitosan hydrogel had rather sta-
ble texture properties at pH 5.8 as can be seen in Table 2.
In 3% chitosan hydrogel at pH close to neutral, the texture
forces (both force 1 and force 2) were found to be increasing.
This is because of a higher viscosity of 3% chitosan hydrogel at
higher pH. At a low pH, the measured forces (both force 1 and
force 2) were found to be decreasing. The pH is affecting the
swelling and properties of the polymer. Chitosan hydrogel has
a high-ionization degree in acid medium, thus −NH2 groups
are in more protonated (−NH3+) forms than chitosan hydrogel
at pH close to neutral. Therefore, as the hydrogel is mainly in
ionized form, it is able to bind anions of drug by electrostatic
attraction. At low pH, the cohesiveness (Area 1) and the adhe-
siveness of chitosan gel (Area 2) were found to be decreasing.
The increasing pH value of the chitosan formulation results in
more coherent hydrogels as both gel cohesiveness and adhesive-
ness increased. The chitosan network appears to be stable at
higher pH value. The high viscosity induced a higher release of
indomethacin from 3% chitosan hydrogel at pH close to neutral
than 3% chitosan hydrogel at pH 3.8.
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Figure 1. Rheogram of the chitosan gels (without microemulsion)—
1% (a), 1.5% (b), and 2% (c).
Figure 4 shows the effect of concentration of chitosan on re-
leased amounts of indomethacin into different buffer solutions
after 6 h. As evident from the figure, with increasing concentra-
tions of chitosan, released amount of indomethacin rises. The
highest amount of indomethacinwas released from all prepared
3% chitosan gels (with or without microemulsion) in different
buffer solutions.
Statistically significant differences were found (p < 0.05) be-
tween all drug release profiles from the gels in 3% concentration
of chitosan in comparison to 1%, 1.5%, and 2% chitosan gels in
all dissolution mediums used for liberation.
Figure 2. Rheogram of 3% chitosan gel at pH 5.8 (withoutmicroemul-
sion).
Figure 3. Rheogram of 3% chitosan gel at pH 3.8 (withoutmicroemul-
sion).
Drug release rates through the cellulose membranes of mi-
croemulsion formulations were comparedwith the release rates
of the chitosan gels. It was observed that the presence of
microemulsion caused the increased release of indomethacin
from estimated samples (Fig. 4). Table 3 shows a significantly
higher and faster drug release rates across the membrane for
microemulsion–gel mixtures than for pure gels. Release of the
drug through the membrane from microemulsion formulations
was faster, even during the initial hours, than that from pure
gels, which may be because of the fact that indomethacin dis-
solved better in the microemulsion, leading to higher concen-
tration gradients toward the membrane. The high-solubilizing
capacity of microemulsion enables to increase the solubility of
indomethacin in PBS and the possibility of transmembrane de-
livery of a drug incorporated in microemulsion. Microemulsion
provided higher and faster release rate than the gel, which
may be related to the reduction in interfacial tension between
the membrane and vehicle and perhaps because of the larger
Table 2. The Effect of pH on Texture Properties of Chitosan Hydrogels (Without Microemulsion) (3%, w/w) (n = 5)
Type of Hydrogel and
Concentration (%,
w/w)
Force 1 ±SD (g)
(Maximum
Compressing Force;
Hardness)
Area 1 ±SD (g*s)
(Cohesiveness)
Force 2 ±SD (g)
(Minimum
Retracting Force)
Area 2 ±SD (g*s)
(Adhesiveness)
Chitosan, 3 (pH 3.8) 49.440 ± 0.114 104.702 ± 0.311 −36.963 ± 0.188 −73.099 ± 0.870
Chitosan, 3; (pH 5.8) 150.780 ± 1.036 274.666 ± 1.543 −67.069 ± 0.224 −87.173 ± 1.645
Five replicate analyses were performed for each formulation, under the optimized conditions for that type of hydrogel.
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Figure 4. Released amount of indomethacin from chitosan gels and their mixtures with microemulsion in PBS and PBS with 0.5% and 0.75%
(w/w) of SLS after 6 h. ME, microemulsion.
Table 3. Kinetic Parameters of Indomethacin Released from Various Chitosan Gels and Their Mixtures Containing Microemulsion
Dissolution Medium Zero Order: Q = K0 t Higuchi: Q = KH t1/2 Zero Order: Q = K0 t Higuchi: Q = KH t1/2
Gel SLS (%, w/w) K0 (%, min−1) r2/360 min KH (%, min−1/2) r2 Gel* K0 (%, min−1) r2/360 min KH (%, min−1/2) r2
G1% 0 0.0026 0.9403 0.0347 0.6722 G1%* 0.0039 0.8453 0.0477 0.5128
G1% 0.5 0.0036 0.9526 0.0514 0.859 G1%* 0.0034 0.9002 0.0455 0.6310
G1% 0.75 0.0031 0.8694 0.0411 0.626 G1%* 0.0034 0.9541 0.0454 0.6935
G1.5% 0 0.0040 0.9727 0.0552 0.7676 G1.5%* 0.0058 0.8996 0.0742 0.5832
G1.5% 0.5 0.0047 0.9410 0.0641 0.6949 G1.5%* 0.0058 0.8932 0.0735 0.5753
G1.5% 0.75 0.0042 0.9322 0.0553 0.6402 G1.5%* 0.0055 0.9059 0.0709 0.5997
G2% 0 0.0053 0.9813 0.0719 0.7277 G2%* 0.0093 0.9156 0.1188 0.5945
G2% 0.5 0.0083 0.9417 0.1177 0.8392 G2%* 0.0073 0.9575 0.0958 0.6702
G2% 0.75 0.0062 0.9585 0.0813 0.6761 G2%* 0.0077 0.9522 0.1007 0.6517
G3% 0 0.0138 0.9644 0.1974 0.8942 G3%* 0.0204 0.9913 0.2749 0.7405
G3% 0.5 0.0105 0.9882 0.1425 0.7504 G3%* 0.0154 0.9954 0.2135 0.8157
G3% 0.75 0.0101 0.9870 0.1355 0.7362 G3%* 0.0136 0.9827 0.1809 0.7147
G3%** 0 0.0038 0.6965 0.0575 0.9868 G3%** 0.0038 0.5840 0.0585 0.9769
G3%** 0.5 0.0024 0.7123 0.0362 0.9552 G3%** 0.0031 0.7980 0.0470 0.9517
G3%** 0.75 0.0022 0.8856 0.0321 0.9479 G3%** 0.0037 0,9333 0.0533 0.9248
Gel = Gel(%, w/w, of chitosan; Gel* = Gel(%, w/w, of chitosan) containing O/W microemulsion in 4:1 ratio; G3%** = acidified gel; pH 3.8.
viscosity of the chitosan gel as compared with the microemul-
sion, which would have delayed the release of indomethacin
from the pure gel.
As evident from the figure, the presence of the SLS (in con-
centration 0.5% and 0.75%) in PBS caused reduction in the
amount of released indomethacin from samples containing mi-
croemulsion in comparison with the buffer solution without
SLS. This difference may be because of the interaction of poly-
mer and SLS from PBS, which creates the coats of solid gel on
the surface of membranes in donor part, thereby slowing down
the release process.
The higher concentration of SLS in dissolution medium
(0.75%) slightly decreased the release of indomethacin, but the
difference between drug release profiles in PBS containing dif-
ferent concentrations of SLS was found to be statistically non-
significant. Moreover, the presence of SLS in the dissolution
medium also decreased the released amounts of indomethacin
from pure 3% of chitosan gels (Fig. 4).
We found that the concentrations of SLS were decreased in
PBS after 6 h of liberation. In other words, the surface ten-
sions of all dissolution mediums containing SLS slightly in-
creased after 6 h of liberation (Table 1). This means that the
surfactant passed through the membrane into the donor part
and interacted with our sample of chitosan. On this basis, we
can say that the negative influence of SLS on the drug re-
lease is because of the complexation between SLS as an anionic
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Figure 5. The effect of pH on indomethacin released profiles from 3% chitosan gels.
surfactant and chitosan as cationic polymer. SLS exhibits
coulombic and noncoulombic interactions when kept in con-
tact with polymeric surface. Their interactions are influenced
mainly by coulombic forces between the ionic sites of surfac-
tant and polymer. In our experiment, the formation of coat of
solid gel on the surface of membranes in donor part after 6 h
of release in all mediums with SLS was also observed. In the
case of samples with microemulsion, the higher amounts of
drug were released because of the fact that microemulsion pro-
vided higher release rate from these samples. In the presence
of microemulsion, a lower viscosity of these samples was ob-
served what caused that the coats of solid gel on the surface of
membranes in donor part were thinner after 6 h of release.
In the case of 1%, 1.5%, and 2% chitosan gels without mi-
croemulsion, indomethacin was released in higher amount into
the PBS containing SLS in comparison with pure PBS. The for-
mation of solid coat of solid gel on the surface of membranes in
donor part after 6 h of drug liberation was also observed, but
the addition of SLS in PBS could probably enhance the disso-
lution rates of indomethacin by increasing contact between the
drug and the dissolution medium. Further rise in the concen-
tration of SLS to 0.75% in dissolution medium decreased the
release of indomethacin. The CMC of SLS is 8.0 x 10−3 mol/L,
that is, 0.23% at 25◦C. Used concentration of SLS was more
than CMC8,31 and increased by the presence of inorganic salts
in the dissolution medium. The higher ionic strength at higher
concentration of SLS (0.75%) possibly affects the drug release
by complexation with ionized amino groups of chitosan (p <
0.05). The formation of coat of solid gel on the surface of mem-
brane was probably faster at a higher concentration of SLS and
this could reduce the rate of drug release.
In this case, the complex forms layer on the permeationmem-
brane; depending on the concentration of chitosan and SLS, this
can modify the permeation by decreasing the amount of drug
released.
The formation of these complexes may be particularly
useful for the encapsulation or controlled release of certain
components7 and may provide the required physicochemical
properties for the design of specific drug delivery systems.32
As evident from Figure 4, the highest amounts of in-
domethacin were released from all 3% chitosan gels with or
without microemulsion. Varshosaz et al.33 also published that
the release data reveal that increasing the concentration and
molecular weight of chitosan increase the lidocaine release rate
that is not in accordance with viscosity results. In other words,
the higher the shearing rates of the gel, the faster the release
of lidocaine. Senel et al.34 reported an increase in chlorhexidine
gluconate release rate by increasing the chitosan concentration.
In our work, chitosan inhibited the release of indomethacin
from chitosan gels with low content of chitosan at low pH, pos-
sibly because of the formation of an ionic complex between the
amino group of chitosan and carboxyl group of indomethacin.
There was higher amount of released indomethacin from 3%
chitosan samples, which is probably attributable to increased
pH (5.8) and because of higher solubility of indomethacin and
only partial ionization of amino groups (40% chitosan amino
groups are protonated at pH 6.0).35 Figure 5 shows the effect of
pH on released profiles of indomethacin from 3% chitosan sam-
ples with pH 3.8 and 5.8 and their mixtures with microemul-
sion at pH 7.4 phosphate buffer and PBS with 0.5% and 0.75%
content of SLS. From Figure 5, it can be seen that more of
the indomethacin was released from the weakly acidic chitosan
samples (5.8) in which the amino groups of chitosan are not
completely protonized than chitosan samples at the pH 3.8, in
which chitosan should be totally protonated. Chitosan carries
primary amine functional groups and therefore its charge and
solubility are pH dependent. Changes in pH have a clear influ-
ence on the release of the drug.
Polymer–drug interaction plays an important role in the re-
lease behavior of the drug. Hence, polymers interacting with
drugs could be investigated to modulate the release profile of
the drug. The regression data for two kinetic models–zero order
and Higuchi–indicate that all samples containing not acidified
gels follow zero-order kinetics. The amount of indomethacin
released from 3% gel formulations with lower pH–acidified
(G3%**) studied here showed that the data fitted better in the
Higuchi model as indicated by higher r2 values. The plot of
the cumulative indomethacin permeation through the mem-
brane versus square root of time was almost linear, thus indi-
cating diffusion controlled-release kinetics. In other words, the
release of indomethacin from 3% acidified gel formulations is
diffusion rate limited. The acidification of chitosan (pH 3.8) de-
creased drug release rate constants as compared with chitosan
(pH5.8) without change of pH. The principalmechanism of such
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interactions is the formation of hydrogen bonds involving amino
group of chitosan and the carboxyl group of indomethacin. The
drug release rate constants of the test formulations are pre-
sented in Table 3.
These results indicate that chitosan gels could be convenient
for controlled-release delivery systems of different drugs wher-
ever pH-sensitive mechanics might be useful.
CONCLUSIONS
Microemulsion enhanced the liberation of the indomethacin
from chitosan gels into all dissolution mediums. Adding of
the surfactant into PBS decreased the amount of liberated
indomethacin from microemulsion–gel mixtures but increased
the drug liberation from pure chitosan gels with lower concen-
tration of chitosan. With the increased concentration of chi-
tosan in the samples, the released amount of indomethacin
was also increased. Higher pH of the samples was decisive for
the liberation of indomethacin from chitosan gels. The increas-
ing of pH value of the chitosan formulation results in more
coherent hydrogels. Both the gels cohesiveness and adhesive-
ness increased. It appears that higher pH value stabilizes the
chitosan network. The high viscosity induced a higher release
of indomethacin from 3% chitosan hydrogel at pH 5.8 as op-
posed to 3% chitosan hydrogel at pH 3.8. The highest percent-
age of released indomethacin was determined when a mixture
of microemulsion gel with higher chitosan content was used. On
the basis of our previous study,29 it can be concluded that this
prepared chitosan gel with microemulsion is more suitable for
permeation of indomethacin than commercial Indobene GelR©.
Chitosan gels could be convenient for the controlled release of
drugs.
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